SCHEMBL2359337

SCHEMBL2359337

O=C1CCCc2c1[nH]c1ccc(Cl)c(Cl)c21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.56
LMNA P02545 5/20 0.56
GAA P10253 1/20 0.56
HSD17B10 Q99714 5/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
ALDH1A1 P00352 5/20 0.49
HPGD P15428 3/20 0.49
MAPT P10636 2/20 0.49
MAPK1 P28482 1/20 0.49
AR P10275 4/20 0.45
POLB P06746 1/20 0.43
BRD4 O60885 2/20 0.40
ALOX15 P16050 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22529407 0.97 KDM4E (0.52) KDM4ELMNAGAAHSD17B10MEN1
SCHEMBL14688216 0.90 KDM4E (0.46) KDM4ELMNAGAAHSD17B10MEN1
SCHEMBL5271427 0.85 KDM4E (0.54) KDM4ELMNAGAAHSD17B10MEN1
SCHEMBL2359673 0.85 KDM4E (0.57) KDM4ELMNAGAAHSD17B10MEN1
SCHEMBL2360513 0.83 KDM4E (0.54) KDM4ELMNAGAAHSD17B10MEN1
SCHEMBL5273779 0.81 KDM4E (0.50) KDM4ELMNAGAAHSD17B10MEN1
SCHEMBL2360276 0.78 HTT (0.60) KDM4ELMNAGAAHSD17B10MEN1
SCHEMBL2359682 0.75 ALDH1A1 (0.47) KDM4ELMNAGAAHSD17B10MEN1
SCHEMBL2359484 0.75 KDM4E (0.56) KDM4ELMNAGAAHSD17B10MEN1
SCHEMBL18155434 0.75 KDM4E (0.44) KDM4ELMNAGAAHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11458121-B2 Therapeutic compounds and methods to treat infection RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2022-10-04 US disclosed
US-20200155507-A1 THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2020-05-21 US disclosed
US-20200155507-A1 THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2020-05-21 US disclosed
WO-2019005841-A1 THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-01-03 WO disclosed
US-20170121285-A1 Selective androgen receptor modulators RADIUS HEALTH INC (US) 2017-05-04 US disclosed
US-20170121285-A1 Selective androgen receptor modulators RADIUS HEALTH INC (US) 2017-05-04 US disclosed
US-20170121285-A1 Selective androgen receptor modulators RADIUS HEALTH INC (US) 2017-05-04 US disclosed
EP-2531029-B1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2016-10-19 EP disclosed
EP-2531029-B1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2016-10-19 EP disclosed
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2015-09-24 US disclosed
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2015-09-24 US disclosed
US-8987319-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2015-03-24 US disclosed
US-8987319-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2015-03-24 US disclosed
US-8987319-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2015-03-24 US disclosed
US-20130041007-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. 2013-02-14 US disclosed
US-20130041007-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. 2013-02-14 US disclosed
US-20130041007-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. 2013-02-14 US disclosed
EP-2531029-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS Radius Health, Inc. (US) 2012-12-12 EP disclosed
WO-2011097496-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2011-08-11 WO disclosed
WO-2011097496-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121285-A1 Selective androgen receptor modulators AR, SHBG, FSHR KDM4E 1228/4885LMNA 1424/4885GAA 3270/4885
US-11458121-B2 Therapeutic compounds and methods to treat infection ABCB11, SLC10A1, SLC47A1 KDM4E 4461/4885LMNA 4360/4885GAA 204/4885
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS AR, SHBG, FSHR KDM4E 1235/4885LMNA 1414/4885GAA 3263/4885
US-20200155507-A1 THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION ABCB11, SLC10A1, SLC47A1 KDM4E 4461/4885LMNA 4360/4885GAA 204/4885
US-20130041007-A1 Selective Androgen Receptor Modulators AR, SHBG, GPR119 KDM4E 1925/4885LMNA 1447/4885GAA 3815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.